Irinotecan liposomes plus bevacizumab for recurrent glioma
Part of Cancer clinical trials.
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a glioma (brain tumor) that has come back or worsened after your first treatment.
- You have not been treated with irinotecan or irinotecan liposomes before.
- You have at least one brain tumor that can be seen on scans and measured.
- You are in fairly good health (able to do most daily activities) and have good blood, liver, and kidney function.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
This trial tests a new combination of two drugs, entacapone and bevacizumab, for people whose glioblastoma (a type of brain tumor) has returned after initial treatment. The goal is to see if this combination can help control the tumor and improve outcomes.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a combination of two drugs for people with glioblastoma that has come back after treatment with bevacizumab (a drug that targets blood vessel growth). The goal is to see if this new combination can shrink the tumor or slow its growth.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.